晚期乳腺癌不同的化疗方法疗效比较

目的探讨新辅助化疗不同的治疗方案对局部晚期乳腺癌患者的疗效。方法75例接受新辅助化疗的乳腺癌(A期)患者随机分为三组:TA组(n=25,紫杉醇联合吡柔比星),CAF组(n=25,吡柔比星联合环磷酰胺、5-氟尿嘧啶),CMF组(n=25,环磷酰胺联合5-氟尿嘧啶、氨甲喋呤),21d为一个周期,两个周期后对乳腺癌原发病灶及腋窝淋巴结状态进行观察及分析。结果TA组、CMF组和CAF组总有效率分别为83%、63%和25%。TA组与CMF组相比较有显著差异(P<0.05),CAF组与CMF组相比较有显著差异(P<0.05),TA组与CAF组相比较无统计学意义(t=0.022,P>0.05)。结论TA组和CAF组在局部晚期的乳腺癌新辅助治疗的过程中疗效满意,毒副反应可以耐受,值得推广。

Comparison on Therapeutic Effect of Different Chemotherapy in Locally Advanced Breast Cancer

Objective To discuss the therapeutic effect of different chemotherapy in the treatment of advanced breast cancer. Methods Seventy-five patients with advanced breast cancer receiving different newly developed chemotherapy were randomly divided into three groups: Group TA(n=25, paclitaxel and pirarubicin), Group CAF(n=25, pirarubicin, cyclophosphamide and 5-fluorouracil) and Group CMF(n=25, cyclophos-phamide, 5-fluorouracil and methotrexate), each therapeutic course was completed within 21 days. The primary breast cancer and axillary lymphadenopathy were observed at the end after therapeutic courses completed. Results The effective rates of TA, CAF and CMF were 83%, 63%, 25%, respectively. There were significant differences between the TA and CMF groups(P<0.05) and also between the CAF and CMF groups(P<0.05), but not between the TA and CAF groups(P>0.05). Conclusion Group TA and group CAF have satisfactory effect.